Cart
×
Avidity’s trial for individuals with Duchenne amenable to skipping exon 45 is aiming to start in the first half of 2027
Read Avidity’s Community Letter:
Avidity’s New Access Program Marks a Milestone for the Duchenne Community
In 2018, CureDuchenne was the only Duchenne-focused organization to invest in Avidity Biosciences, recognizing the potential of their novel RNA-targeting approach for individuals with Duchenne muscular dystrophy long before it reached clinical trials. […]
Avidity Biosciences to be acquired by Novartis
Updated: December 4, 2025 From Belief to Breakthrough: Celebrating Avidity’s Potential Acquisition by Novartis In 2018, CureDuchenne made a bold investment in a promising company with an idea that could […]
Avidity Biosciences Announces Positive AOC 1044 Data
Avidity Biosciences, which received early funding from CureDuchenne, announced positive initial data from their EXPLORE44 Trial for individuals with Duchenne amenable to skipping exon 44. Their experimental exon-skipping agent, AOC […]
Avidity Biosciences Webinar: EXPLORE44
A Clinical Trial Investigating the Potential for AOC 1044 to Treat Individuals with DMD Mutations Amenable to Exon 44 Skipping Join Cure Duchenne’s webinar as we welcome Kelly DiTrapani and […]